<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="366345">
  <stage>Registered</stage>
  <submitdate>15/05/2014</submitdate>
  <approvaldate>20/05/2014</approvaldate>
  <actrnumber>ACTRN12614000531617</actrnumber>
  <trial_identification>
    <studytitle>Can reduced dose radiotherapy delivered in standard fractionation improve the therapeutic index for stereotactic treatment of juxtapapillary choroidal melanoma?</studytitle>
    <scientifictitle>Can reduced dose radiotherapy delivered in standard fractionation improve the therapeutic index for stereotactic treatment of juxtapapillary choroidal melanoma?</scientifictitle>
    <utrn>U1111-1156-8748</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Juxtapapillary choroidal melanoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Malignant melanoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Reduced dose fractionated stereotactic radiotherapy (FSRT) to a dose of 60Gy in 30 fractions given 5 fractions per week. The overall duratioin of FSRT treatment is 6 weeks.</interventions>
    <comparator>Uncontrolled</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Distant metastasis free survival (DMFS): DMFS is defined as the time from the date of start of radiotherapy to the date of the first distant metastasis or date of death without distant metastasis. DMFS will be censored by the closeout date and the date of the last follow-up for patients lost to follow-up.</outcome>
      <timepoint>5 years after completion of accrual.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Freedom from local progression (FFLP): FFLP is defined as the time from the date of start of radiotherapy to the date of the first local progression.  Death and distant metastasis will be considered censoring events. FFLP will be censored by the closeout date for patients alive and without progression and by the date of the last follow-up for patients lost to follow-up. </outcome>
      <timepoint>5 years after completion of accrual.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Enucleation: Enucleation will be recorded as having occurred or not. The reason for enucleation will be i) tumour progression within the eye, ii) radiation toxicity or iii) other. </outcome>
      <timepoint>5 years after completion of accrual.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Visual Acuity (VA) will be measured by the treating ophthalmologist using a Snellen Chart. </outcome>
      <timepoint>5 years after completion of accrual. VA is assessed at Baseline, and then annually up to 10 years.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Radiation late effects will be assessed by the ophthalmologist at clinical follow-up. The Common Terminology Criteria version 4.0 (CTC v4.0). </outcome>
      <timepoint>5 years after completion of accrual. Radiation late effects will be assessed at 3, 6, 12, 18 and 24 months after completion of radiotherapy.  There will then be annual assessment up to 10 years after completion of radiotherapy. </timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Primary choroidal melanoma (small and medium sized)
 - A clinical diagnosis of CM made by a suitably trained ophthalmologist is mandatory 
 - Features that define CM and must be present are a choroidal mass that is pigmented or hypopigmented AND EITHER: 
a) Tumour height measured on beta ultrasound to be 2.5mm or greater OR
b) Documented growth of a lesion &lt;2.5mm in height
2. Tumour height to 8mm or less
3. Tumour basal diameter 16mm or less
4. Visual acuity better than 6/60 ( or 0.1) 
5. No evidence of metastatic disease on liver ultrasound
6. Age 70 or less
7. An ECOG performance status score of 0 - 2
8. Participants capable of childbearing are using adequate contraception
9. Available for follow up 
10. Has provided written Informed Consent for participation in this trial</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Tumour involving the iris or ciliary body
2. Cytopathologic diagnosis is not uveal melanoma
3. Previous treatment to the affected eye with radiation, laser or thermotherapy
4. Non-malignant disease of the affected eye (that already has or could affect vision) 
5. Known to have diabetes mellitus
6. Prior diagnosis of cancer that was:
 - more than 5 years prior to current diagnosis with subsequent evidence of disease recurrence or clinical expectation of recurrence is greater than 10%
 - within 5 years of current diagnosis with the exception of successfully treated basal cell or squamous cell skin carcinoma or carcinoma in situ of the cervix
7. Patients with clinical evidence of metastatic disease.
8. Women who are pregnant 
9. Unable to give informed consent</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>The Investigator should ensure that all of the following requirements are met prior to patient enrolment:
1. The patient meets all inclusion criteria and none of the exclusion criteria apply.
2. The patient has signed and dated all applicable consent forms.
3. All baseline assessments and investigations have been performed and recorded in the patientsâ€™ medical records (i.e. source documents).
4. The registration and eligibility Case Report Form(s) (CRF) has been completed, signed and dated by the Investigator</concealment>
    <sequence>This is a single arm pilot study.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 0</phase>
    <anticipatedstartdate>1/07/2014</anticipatedstartdate>
    <actualstartdate>15/12/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Peter MacCallum Cancer Centre - Melbourne</hospital>
    <postcode>3000 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Peter MacCallum Cancer Centre</primarysponsorname>
    <primarysponsoraddress>305 Grattan Street
Melbourne VIC 3000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>The Royal Australian and New Zealand College of Radiologists </fundingname>
      <fundingaddress>Level 9
51 Druitt Street
Sydney NSW 2000 </fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this research project is to study whether it is possible to use a lower total dose of fractionated stereotactic radiotherapy (FSRT) and small daily radiation treatments to treat choroidal melanoma, in order to increase the chance of keeping vision in the eye and to reduce the severity of radiation side-effects but without affecting the chance of cure. 

Who is it for? 
You may be eligible to join this study if you are aged less than or equal to 70 years and have been diagnosed with primary choroidal melanoma (small and medium sized) by an ophthalmologist. You should not have received previous treatment to the affected eye with radiation, laser or thermotherapy. 

Study details 
All participants in this study will receive reduced dose FSRT to a dose of 60Gy in 30 fractions, given 5 fractions per week over 6 weeks. It is known that small daily doses of radiation (2Gy) will protect normal tissues from radiation injury when compared with large daily doses. When small daily doses are used it is called full fractionation. Tissues such as the eye nerve and the blood vessels at the back of the eye are especially protected by full fractionation. FSRT is a technology that makes it possible to use full fractionation to treat choroidal melanoma, so this may make it possible to reduce side-effects and keep better vision in the eye. 

Participants will be followed for up to 10 years to evaluate disease response, vision and any radiation side-effects. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Peter MacCallum Cancer Centre Ethics Committee</ethicname>
      <ethicaddress>Ethics Committee Secretariat
Locked Bag 1, A'Beckett Street
Melbourne VIC 8006</ethicaddress>
      <ethicapprovaldate>1/09/2014</ethicapprovaldate>
      <hrec>14/71</hrec>
      <ethicsubmitdate>15/05/2014</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Claire Phillips</name>
      <address>Peter MacCallum Cancer Centre
Locked Bag 1, A'Beckett Street
Melbourne VIC 8006</address>
      <phone>+61 3 8559 5000</phone>
      <fax>+61 3 9656 7719</fax>
      <email>Claire.Phillips@petermac.org</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Jenny Trinh</name>
      <address>Peter MacCallum Cancer Centre
Locked Bag 1, A'Beckett Street
Melbourne VIC 8006</address>
      <phone>+61 3 8559 8482</phone>
      <fax>+61 3 8559 7719</fax>
      <email>Jenny.Trinh@petermac.org</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Claire Phillips</name>
      <address>Peter MacCallum Cancer Centre
Locked Bag 1, A'Beckett Street
Melbourne VIC 8006</address>
      <phone>+61 3 8559 5000</phone>
      <fax>+61 3 8559 7719</fax>
      <email>Claire.Phillips@petermac.org</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Jenny Trinh</name>
      <address>Peter MacCallum Cancer Centre
Locked Bag 1, A'Beckett Street
Melbourne VIC 8006</address>
      <phone>+61 3 8559 8482</phone>
      <fax>+61 3 8559 7719</fax>
      <email>Jenny.Trinh@petermac.org</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>